Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design
- PMID: 11481348
- DOI: 10.1200/JCO.2001.19.15.3445
Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design
Comment on
-
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.J Clin Oncol. 2001 Aug 1;19(15):3447-55. doi: 10.1200/JCO.2001.19.15.3447. J Clin Oncol. 2001. PMID: 11481349 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical